Original Publication Date: >1 June, 2017
Publication / Source: Future Science OA
Authors: Balamurugan A Vellayappan, Lia M Halasz, Jonathan PS Knisely, Eric L Chang & Simon S Lo
Glioblastoma (GBM) is the most common malignant primary brain tumour. It disproportionately affects the older segment of the population, as approximately half of the patients with GBM are above 65 years [1,2]. Moreover, the aging of the baby boom generation foreshadows a ‘silver tsunami’ of GBM .
Overlapping problems complicate management decisions for elderly patients, whether or not they have GBM. These may include multiple comorbidities and poor physiologic reserves, polypharmacy, limited mobility, cognitive decline, and social and financial vulnerability . In addition, survival among elderly patients with GBM has been consistently shorter than among younger patients, with a population based median survival of approximately 6 months (m) . It is unclear if this is due to more aggressive tumor biology , the use of less intense treatment approaches  or increased susceptibility to treatment toxicities .